Strategic pricing of new pharmaceuticals

被引:132
作者
Lu, ZJ [1 ]
Comanor, WS [1 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
D O I
10.1162/003465398557212
中图分类号
F [经济];
学科分类号
02 ;
摘要
This paper provides empirical evidence on the leading factors affecting the prices of new pharmaceuticals, bath at introduction and after 4, 6, and 8 years. Most important is the extent of therapeutic advance embodied in a new product, For drugs which represent important therapeutic gains, launch prices can be two or three times those of existing drugs used for the same purposes, while drugs that largely duplicate the actions of currently available products are typically priced al comparable levels. In addition, the number of branded substitutes has a substantial negative effect on launch prices, which reflects the importance of competitive pressures. Duplicate products thereby play an important economic role in pharmaceutical markets.
引用
收藏
页码:108 / 118
页数:11
相关论文
共 39 条
[1]  
*AM MED ASS, DRUG EV
[2]  
BAGWELL K, 1991, AM ECON REV, V81, P224
[3]   NEW PRODUCT GROWTH FOR MODEL CONSUMER DURABLES [J].
BASS, FM .
MANAGEMENT SCIENCE SERIES A-THEORY, 1969, 15 (05) :215-227
[4]  
CAVES RE, 1991, BROOKINGS PAPERS EC, P3
[5]  
COMANOR WS, 1986, J ECON LIT, V24, P1178
[6]  
COMANOR WS, 1995, STRUCTURE AM IND, P177
[7]   PRICING PIONEERING PRODUCTS [J].
DEAN, J .
JOURNAL OF INDUSTRIAL ECONOMICS, 1969, 17 (03) :165-179
[8]   EXPERIENCE CURVES AND DYNAMIC DEMAND MODELS - IMPLICATIONS FOR OPTIMAL PRICING STRATEGIES [J].
DOLAN, RJ ;
JEULAND, AP .
JOURNAL OF MARKETING, 1981, 45 (01) :52-62
[9]  
EATON BC, 1989, HDB IND ORG, V1, P723, DOI DOI 10.1016/S1573-448X(89)01015-0
[10]  
*FACTS COMP DIV, 1977, DRUGS FACTS COMP